Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Thomas Köhnke"'
Autor:
Amy C. Fan, Yusuke Nakauchi, Lawrence Bai, Armon Azizi, Kevin A. Nuno, Feifei Zhao, Thomas Köhnke, Daiki Karigane, David Cruz-Hernandez, Andreas Reinisch, Purvesh Khatri, Ravindra Majeti
Publikováno v:
The Journal of Clinical Investigation, Vol 133, Iss 19 (2023)
Disease-initiating mutations in the transcription factor RUNX1 occur as germline and somatic events that cause leukemias with particularly poor prognosis. However, the role of RUNX1 in leukemogenesis is not fully understood, and effective therapies f
Externí odkaz:
https://doaj.org/article/9d67e910a2aa4c2186e242f58f9edee6
Autor:
Thomas Köhnke, Xilong Liu, Sascha Haubner, Veit Bücklein, Gerulf Hänel, Christina Krupka, Victor Solis-Mezarino, Franz Herzog, Marion Subklewe
Publikováno v:
Biomarker Research, Vol 10, Iss 1, Pp 1-13 (2022)
Abstract Background Immunotherapy of acute myeloid leukemia has experienced considerable advances, however novel target antigens continue to be sought after. To this end, unbiased approaches for surface protein detection are limited and integration w
Externí odkaz:
https://doaj.org/article/3deaa18de5b24156b55d8e2a8330a8ea
Autor:
Rajiv Sharma, Daniel P. Dever, Ciaran M. Lee, Armon Azizi, Yidan Pan, Joab Camarena, Thomas Köhnke, Gang Bao, Matthew H. Porteus, Ravindra Majeti
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021)
Genetic barcoding has been used to track clonal dynamics of cells. Here, the authors develop a Tracking Recombination Alleles in Clonal Engraftment using sequencing (TRACE-Seq), to barcode repaired alleles by introducing silent mutations or outside o
Externí odkaz:
https://doaj.org/article/24227f1bebe84818bfcc9151aa481b5d
Autor:
Felix S Lichtenegger, Frauke M Schnorfeil, Maurine Rothe, Katrin Deiser, Torben Altmann, Veit L Bücklein, Thomas Köhnke, Christian Augsberger, Nikola P Konstandin, Karsten Spiekermann, Andreas Moosmann, Stephan Boehm, Melanie Boxberg, Mirjam HM Heemskerk, Dennis Goerlich, Georg Wittmann, Beate Wagner, Wolfgang Hiddemann, Dolores J Schendel, Gunnar Kvalheim, Iris Bigalke, Marion Subklewe
Publikováno v:
Clinical & Translational Immunology, Vol 9, Iss 3, Pp n/a-n/a (2020)
Abstract Objectives Innovative post‐remission therapies are needed to eliminate residual AML cells. DC vaccination is a promising strategy to induce anti‐leukaemic immune responses. Methods We conducted a first‐in‐human phase I study using TL
Externí odkaz:
https://doaj.org/article/3a4d0c120cb84fcc870ac9dc0f5bdade
Autor:
Thomas Köhnke, Veit Bücklein, Sandra Rechkemmer, Stephanie Schneider, Maja Rothenberg-Thurley, Klaus H. Metzeler, Maria-Cristina Sauerland, Wolfgang Hiddemann, Karsten Spiekermann, Marion Subklewe
Publikováno v:
Haematologica, Vol 104, Iss 11 (2019)
Externí odkaz:
https://doaj.org/article/ea6d1acb6a844b5ba8d4e7cdfde846d9
Publikováno v:
Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-20 (2017)
Abstract The advent of new immunotherapeutic agents in clinical practice has revolutionized cancer treatment in the past decade, both in oncology and hematology. The transfer of the immunotherapeutic concepts to the treatment of acute myeloid leukemi
Externí odkaz:
https://doaj.org/article/689bddaf940e40dc9633a5375c418ee6
Publikováno v:
International Journal of Molecular Sciences, Vol 20, Iss 10, p 2425 (2019)
In spite of therapeutic improvements in the treatment of different hematologic malignancies, the prognosis of acute myeloid leukemia (AML) treated solely with conventional induction and consolidation chemotherapy remains poor, especially in associati
Externí odkaz:
https://doaj.org/article/39115a518e3a4b6c8946008ec445e433
Autor:
Max Hubmann, Thomas Köhnke, Eva Hoster, Stephanie Schneider, Annika Dufour, Evelyn Zellmeier, Michael Fiegl, Jan Braess, Stefan K. Bohlander, Marion Subklewe, Maria-Cristina Sauerland, Wolfgang E. Berdel, Thomas Büchner, Bernhard Wörmann, Wolfgang Hiddemann, Karsten Spiekermann
Publikováno v:
Haematologica, Vol 99, Iss 8 (2014)
Monitoring minimal residual disease is an important way to identify patients with acute myeloid leukemia at high risk of relapse. In this study we investigated the prognostic potential of minimal residual disease monitoring by quantitative real-time
Externí odkaz:
https://doaj.org/article/201c4346a69c45b491ad3984a46c0ffc
Autor:
Miles H. Linde, Amy C. Fan, Thomas Köhnke, Aaron C. Trotman-Grant, Sarah F. Gurev, Paul Phan, Feifei Zhao, Naomi L. Haddock, Kevin A. Nuno, Eric J. Gars, Melissa Stafford, Payton L. Marshall, Christopher G. Dove, Ian L. Linde, Niklas Landberg, Lindsay P. Miller, Robbie G. Majzner, Tian Yi Zhang, Ravindra Majeti
Publikováno v:
Cancer Discovery. 13:1164-1185
Therapeutic cancer vaccination seeks to elicit activation of tumor-reactive T cells capable of recognizing tumor-associated antigens (TAA) and eradicating malignant cells. Here, we present a cancer vaccination approach utilizing myeloid-lineage repro
Autor:
Daniel Thomas, Manhong Wu, Yusuke Nakauchi, Ming Zheng, Chloe A.L. Thompson-Peach, Kelly Lim, Niklas Landberg, Thomas Köhnke, Nirmal Robinson, Satinder Kaur, Monika Kutyna, Melissa Stafford, Devendra Hiwase, Andreas Reinisch, Gary Peltz, Ravindra Majeti
Publikováno v:
Cancer Discovery. 13:496-515
Isocitrate dehydrogenase 1 and 2 (IDH) are mutated in multiple cancers and drive production of (R)-2-hydroxyglutarate (2HG). We identified a lipid synthesis enzyme [acetyl CoA carboxylase 1 (ACC1)] as a synthetic lethal target in mutant IDH1 (mIDH1),